EUVIMEDEUVIMED entdecken
Crossref

Low dose anti-thymocyte globulin versus basiliximab as induction in standard risk kidney transplant patients: 5-year follow-up

Candy Cahilog, Romina Danguilan, Paolo Miguel David, Mel-Hatra Arakama, Glenda Eleanor Pamugas

Korean Journal of Transplantation · 2020

DOI: 10.4285/atw2020.op-1026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Korean Journal of Transplantation, 2020. Verfasst von Candy Cahilog und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Cahilog, C., Danguilan, R., David, P. M., Arakama, M., & Pamugas, G. E. (2020). Low dose anti-thymocyte globulin versus basiliximab as induction in standard risk kidney transplant patients: 5-year follow-up. Korean Journal of Transplantation. https://doi.org/10.4285/atw2020.op-1026

Vancouver

Cahilog C, Danguilan R, David PM, Arakama M, Pamugas GE. Low dose anti-thymocyte globulin versus basiliximab as induction in standard risk kidney transplant patients: 5-year follow-up. Korean Journal of Transplantation. 2020. doi:10.4285/atw2020.op-1026

BibTeX
@article{Cahilog2020,
  author = {Cahilog, Candy and Danguilan, Romina and David, Paolo Miguel and Arakama, Mel-Hatra and Pamugas, Glenda Eleanor},
  title = {Low dose anti-thymocyte globulin versus basiliximab as induction in standard risk kidney transplant patients: 5-year follow-up},
  journal = {Korean Journal of Transplantation},
  year = {2020},
  doi = {10.4285/atw2020.op-1026}
}
Kostenlos starten →